Ditzel, Henrik by unknown
Syddansk Universitet
On the performance of de novo pathway enrichment
Batra, Richa; Alcaraz, Nicolas; Gitzhofer, Kevin; Pauling, Josch K.; Ditzel, Henrik; Hellmuth,
Marc; Baumbach, Jan; List, Markus
Published in:






Publisher's PDF, also known as Version of record
Document license
CC BY
Citation for pulished version (APA):
Batra, R., Alcaraz, N., Gitzhofer, K., Pauling, J., Ditzel, H. J., Hellmuth, M., ... List, M. (2017). On the
performance of de novo pathway enrichment. n p j Systems Biology and Applications, 3, [6]. DOI:
10.1038/s41540-017-0007-2
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 05. Jul. 2017
ARTICLE OPEN
On the performance of de novo pathway enrichment
Richa Batra 1,2,3, Nicolas Alcaraz 1,4, Kevin Gitzhofer5, Josch Pauling6, Henrik J. Ditzel 4,7, Marc Hellmuth5,8, Jan Baumbach1,9 and
Markus List 10
De novo pathway enrichment is a powerful approach to discover previously uncharacterized molecular mechanisms in addition to
already known pathways. To achieve this, condition-speciﬁc functional modules are extracted from large interaction networks. Here,
we give an overview of the state of the art and present the ﬁrst framework for assessing the performance of existing methods. We
identiﬁed 19 tools and selected seven representative candidates for a comparative analysis with more than 12,000 runs, spanning
different biological networks, molecular proﬁles, and parameters. Our results show that none of the methods consistently
outperforms the others. To mitigate this issue for biomedical researchers, we provide guidelines to choose the appropriate tool for
a given dataset. Moreover, our framework is the ﬁrst attempt for a quantitative evaluation of de novo methods, which will allow the
bioinformatics community to objectively compare future tools against the state of the art.
npj Systems Biology and Applications  (2017) 3:6 ; doi:10.1038/s41540-017-0007-2
INTRODUCTION
Modern high-throughput OMICS technologies (genomics,
transcriptomics, proteomics, metabolomics, etc.) are driving the
exponential growth of biological data. With continuously decreas-
ing costs, it is now possible to determine the activity of
genes, proteins and metabolites, their chemical modiﬁcation
(phosphorylation, methylation, etc.), as well as mutations on a
genome scale. For example, the gene expression omnibus (GEO)
alone hosts >51,000 study records derived from >1600 organ-
isms.1 Moreover, many international consortia have gathered data
from thousands of samples, for instance, the International Cancer
Genome Consortium2 has collected data on 50 cancer types
derived from several OMICS technologies. To gain a holistic view
of such huge datasets, network-based analysis has become a
promising alternative to traditional enrichment approaches such
as gene ontology enrichment3 or gene set enrichment analysis.4
The objective is to study condition-speciﬁc systemic changes by
projecting experimental data on network modules, representing
conditionally perturbed biological processes. Despite the inherent
noise and incompleteness of currently available networks,
network-based analysis has compelling advantages. It can capture
the modular interplay of biological entities and processes over-
looked in traditional enrichment methods5 and can further
unravel molecular interactions not covered in well-deﬁned path-
ways.6 In addition, network- based pathway enrichment methods
can unravel crosstalk between pathways or sub-mechanisms
which remain undetected in traditional pathway enrichment
methods with known pathways such as KEGG or Reactome.7
De novo pathway enrichment
Over the years, several approaches have been proposed for
network-based analysis of experimental data. While some
methods exploit network topology to augment scoring of known
pathways4, 8–16, others rely on experimental data to reconstruct a
condition-speciﬁc interaction network17–20. Here, we focus on
methods that perform de novo pathway enrichment. These
methods integrate experimental data with a large-scale interac-
tion network, to extract sub-networks enriched in biological
entities active in a given experimental dataset. The deﬁnition of
active depends on the type of dataset, for instance, differential
expression in the case of gene expression data.
Diverse strategies for de novo pathway enrichment methods
have been devised. To summarize the state of the art, we classify
existing methods into four categories (Supplementary Fig. 1): (1)
aggregate score optimization methods, (2) module cover
approaches, (3) score propagation approaches, and (4)
clustering-based approaches. Detailed descriptions of these
classes are provided in the supplementary material. While several
such methods exist (see Table 1), there are no guidelines to aid
potential users in the choice of the appropriate tool. To ﬁll this
gap, we present a comparative analysis of selected tools across
different datasets and parameter settings, as well as propose the
ﬁrst gold standard for quantitative benchmarking of de novo
pathway enrichment methods (Fig. 1).
Challenges in evaluating de novo pathway enrichment tools
Pathway enrichment methods belong to the family of unsuper-
vised statistical learning algorithms. In this context, unsupervised
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means that the quality of potential solutions cannot be assessed
objectively unless the optimal solution is known a priori, i.e., a gold
standard is needed.
In case of de novo pathway enrichment, such a gold standard
consists of genes known to be relevant (or irrelevant) to the
condition(s) measured in the experimental data. In other words, a
set of foreground genes (FG) and a set of background genes (BG)
are required, such that one can utilize the proportion of FG genes
(relevant) compared to BG genes (irrelevant) in the extracted sub-
networks as a performance measure. In the following, we discuss
why such a gold standard is currently unavailable.
The disease- speciﬁc pathways of the KEGG database21 could be
considered as a potential gold standard, as they cover many
known genes (and their interplay) associated with a certain
disease or biological function. However, these genes constitute an
incomplete FG gene set, since it is unlikely that all disease-
associated genes are known. Furthermore, there is no distinction
of potential FG genes and BG gene sets. This bias prohibits a fair
and robust evaluation of de novo pathway enrichment tools using
such databases.
To address this issue, we propose a protocol to generate
artiﬁcial, bias-free gold standard FG and BG datasets. Our
approach relies on two main assumptions:
Signal strength. Signal strength also known as signal to noise
ratio, it describes the dissimilarity of the expression values for a
given set of FG genes compared to the remaining BG genes. The
higher the signal strength, the more diverse are the expression
proﬁles of the FG genes compared to the BG genes. Thus, we can
expect pathway enrichment methods to identify them more
easily.
Sparsity. It models the average distance between FG genes in
the graph. The lower the sparsity, the more densely the FG genes
are distributed over the network, such that pathway enrichment
methods are expected to ﬁnd them more easily.
Analysis strategy. We systematically generated test expression
datasets with preselected (synthetically) FG and BG genes sets.
Subsequently, representative de novo network enrichment tools
were applied to identify FG-rich (and BG-poor) modules across
parameter sets for each tool and for varying problem complexities,
i.e. different levels of signal strength and sparsity. We used two
common protein-protein interaction networks, namely the human
protein reference database (HPRD)22 and the interlogous interac-
tion database (I2D).23
RESULTS
The effect of varying signal strength
We generated expression proﬁles with varying mean (VM) and
varying variation (VV) (see Fig. 4 and “Methods” for details).
Figure. 2a and b illustrate that with increasing signal strength
generally improves the performance of all tools.
BioNet, GXNA, and KeyPathwayMiner (KPM) performed best
with VM. However, if the simulation of expression proﬁles was
based on changes in the variance (VV) between FG and BG
distributions, the top performers BioNet and GXNA performed
poorly. We speculate that this was due to their internal expression
proﬁle preprocessing procedures. Thus, one should carefully
consider the characteristics of FG and BG expression proﬁles in
the choice of the most suitable tool.
The effect of varying sparsity
We used two algorithms to distribute the label FG across the
nodes in the network. The seed-and-extend (SAE) algorithm
generates connected random sub-networks of a particular size
and labels all its nodes as FG. In contrast, the average-distance-k
(AVDK) algorithm distributes the FG node labels such that their
average pairwise distance equals a given k. With increasing k
values, the sparsity grows. All other nodes in the network were
labeled as BG. We computed the sparsity of the FG nodes with
three measures (a) Global FG proximity: Shortest path covering the
FG set nodes in the network. (b) Global FG connectivity: Average
degree of the FG nodes in the network. (c) Local FG density: Graph
density of the FG nodes.
As expected and depicted in Fig. 2c and d, the performance of
all tools decreased with increasing sparsity (decreasing FG
proximity, i.e. increasing k using AVDk). Supplementary Fig. 2
further illustrates the performance dynamics with increasing FG
density and connectivity. Evidently, all tools performed better with
FG nodes selected using the SAE method (Supplementary Fig. 3).
However, biological processes are complex and interaction
networks are incomplete. Genes that are deregulated in a
condition/disease may not be directly connected in the cellular
network. Consequently, we believe that generally AVDk is a better,
more natural choice for FG selection. The results for the I2D
network are depicted in Supplementary Figs 4 and 5.
The effect of varying internal parameters
We can further categorize tools based on the characteristic of their
internal parameters (IP). COSINE, GiGA, GXNA, and PinnacleZ
restrict the solution to a user-speciﬁed size. In contrast, BioNet,
DEGAS and KPM allow for noise (exceptions or outliers) in the
reported solutions, such that sub-networks can have arbitrary size
Table 1. List of publicly available de novo network enrichment
methods in alphabetical order (February 7, 2016)
Tool Method Software Reference
BioNet* ASO app Ref. 25
ClustEx Clust. app Ref. 32
cMonkey Clust. app Ref. 33
COSINE* SP app Ref. 26
GiGA* SP app Ref. 34
GXNA* SP app Ref. 29
HotNet SP app Ref. 35
jActiveModules ASO C-PL Ref. 36
KeyPathwayMiner* MC app, C-PL, WS Ref. 30
DEGAS* MC app Ref. 37
MEMCover MC app Ref. 38
NetWalker ASO app Ref. 16
NetworkTrail ASO WS Ref. 39
PinnacleZ* ASO app, C-PL Ref. 31
ReactomeViz-MCL Clust. C-PL Ref. 40
RegMOD SP app Ref. 41
ResponseNet ASO WS Ref. 42
SubExtract ASO app Ref. 43
TieDIE SP script (Python) Ref. 44
De novo methods capable of processing gene expression data are sub-
divided into four categories, i.e. ASO aggregate score optimization, SP score
propagation, MC module cover and Clust clustering based; see supple-
mentary material for details. The availability of the tool as a stand-alone
application (app), as Cytoscape plugin (C-PL), or as web service (WS) is
further indicated.
* Included in our quantitative study (see text for details)
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within certain constraints to allow for noise. We tested each
selected method on a wide range of IP values. Overall, the trend
was that with increasing IP values the size of the solution increases
(Fig. 3). Lower IP values led to solutions with fewer nodes, whereas
higher IP values led to larger sub-networks. As expected, the
performance (F-measure) decreased towards the extreme ends of
the IP range.
Summary
Consistently across the two tested networks (HPRD and I2D),
BioNet, COSINE, GXNA, and PinnacleZ performed better with
expression data generated using VM as compared to VV. DEGAS
yielded better results with VV, while the performance of KPM and
GiGA was independent of VV and VM. When using VM GiGA,
BioNet, GXNA, and KPM showed better performance with SAE
(dense FG nodes) compared to AVDK (relatively sparse). COSINE,
DEGAS, and PinnacleZ appeared less affected. These trends were
conserved across the two networks. Using HPRD as a network
base, KPM, DEGAS, and GiGA performed better with VV with both
FG node selection algorithms. All tools performed poorly with VV
and AVDK when using I2D. However, when using SAE instead, KPM
and GiGA performed very well.
Based on our analysis, we propose the following guidelines for
biomedical researchers, (a) if computationally feasible, choose a
comprehensive biological network such as I2D for capturing a
wide range of known or predicted biological interactions (b) apply
several tools to obtain a comprehensive picture of the information
captured in the dataset. In any case, a wide range of IP should be
tested. Please note that apart from gene expression proﬁles, some
tools can be used for other types of OMICS data (molecular
proﬁles) such as protein expression proﬁles or RNA sequencing
data.
DISCUSSION AND CONCLUSION
De novo pathway enrichment is a powerful method to uncover
condition-speciﬁc functional modules in molecular biological
networks. Existing methods for integrating networks and experi-
mental data have recently been reviewed in Mitra et al.6 Never-
theless, systematic and quantitative evaluations of the
performance of existing methods and methodology to do so,
have yet to be published.
To establish a basis for such a comparison in the absence of a
suitable gold standard, we propose a strategy to assess the
performance of de novo pathway enrichment tools on simulated
data. We sampled nodes in the network (e.g. genes) that are
relevant in a condition from a foreground distribution and non-
relevant nodes from a background distribution. By adjusting the
sparsity and signal strength of the solutions “hidden” in the
network, we were able to adjust the difﬁculty of the de novo
pathway enrichment problem and systematically compare the
performance of selected tools.
We compared seven tools, representing diverse methodological
approaches, to study the inﬂuence of data preprocessing and
parameter choice on the quality of the solutions. In our analysis,
BioNet and KPM often performed best, presumably because these
tools leave the preprocessing (computation of p-values from
Fig. 1 A typical workﬂow for de novo pathway enrichment. The underlying hypothesis is that phenotype-speciﬁc genes (foreground, FG) are
differentially expressed in many case samples compared to a control group (1, 2) By using statistical tests, one can determine which genes are
affected by the phenotype (3) and overlay this information on an interaction network (4) De novo pathway enrichment tools aim to extract
sub-networks enriched with phenotype-speciﬁc FG genes (5) Comparing several such methods is an open issue
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expression data, for instance) to the user. Our results show that, in
absence of a well-deﬁned gold standard, using two or three
different tools can provide a comprehensive picture of the
information content of the data. In the future, we hope to extend
our framework to a platform for meta or ensemble analysis using
several tools in conjunction. Such a method could, for instance,
combine results from different tools into concatenated (sub-)
networks.
The framework presented here allows for the ﬁrst standardized,
well-structured and comprehensive evaluation of de novo path-
way enrichment methods. However, the design of an optimal
benchmark scheme relies on reasonable model assumptions and
is a challenging task. Our conclusions are limited by nature, as we
have no a priori gold standard datasets. While our knowledge of
disease relevant genes continuously improves, we still lack sets of
non-relevant genes in certain diseases. Nevertheless, we may
assume that disease genes are generally closer to each other in a
molecular biological network,24 and that their expression (in
general) is differentially distributed compared to non-disease
genes. Considering this, we believe to offer a reasonable test
scenario for de novo pathway enrichment methods. However, we
acknowledge that existing methods are diverse in methodology as
well as in their expected input datatypes and formats. As their
performance and ranking varies greatly with their IP and the
characteristics of the expression datasets, all rankings should be
carefully interpreted. While simulated data are suitable for
objective comparisons, we acknowledge that we cannot fully
model the complexity of biological systems. A promising way
forward would be to use large-scale perturbation experiments,




For our analysis, we selected methods available as standalone applications,
a prerequisite for a systematic and automated analysis across different
datasets and parameters. We further restricted our comparison to tools
designed for pathway enrichment using gene expression data, since it is
the most common application type. The following seven tools fulﬁll both
inclusion criteria: (a) BioNet25 is an aggregate score optimization method
that implements an efﬁcient integer linear programming approach to
compute optimal sub-networks. (b) COSINE26 is a score propagation
method that includes not only nodes but also edges in its scoring function.
Edges correspond to differential gene–gene co-expression across different
groups. (c) DEGAS27 is a module cover approach that uses a shortest path
heuristic to identify sub-networks with at least K “active” nodes, with
“active” being deﬁned via the proportion of active cases in the
experimental data. (d) GiGA28 is another score propagation method that
Fig. 2 Average performance for over 80 FG sets of size 20 nodes were generated, using the AVDk algorithm, with varying signal strength (a, b)
and varying sparsity (c, d). Expression proﬁles were simulated with varying mean (VM) (a, c) and varying variation (VV) (b, d). The HPRD
network was used as the input network and the performance was assessed using the F-measure. The error-bars (a, b) and box plots (c, d)
represent performance over several FG nodes and over a range of internal parameter settings for each tool. The higher the signal strength, the
more different are the expression proﬁles of the FG vs. BG genes, indicating that we can expect pathway enrichment methods to identify
them more easily. For details on internal parameters, signal strength and sparsity values, please refer to Supplementary Tables 1, 3, 5
respectively
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Fig. 3 Average performance for over 80 FG sets of size 20 nodes generated using the AVDk algorithm. Expression proﬁles were simulated with
VM. The HPRD network was used as the input network. Performance was assessed with the F-measure for a range of internal parameter
settings for each tool, i.e. the expected pathway size (M) for GXNA, the number of allowed exceptions (outliers) in a pathways (L) for KPM, and
the pathway false discovery rate (FDR) for BioNet
On the performance of de novo pathway enrichment
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ﬁrst computes local minima to serve as starting points for iteratively
building sub-networks with n members and a maximal rank of m.
(e) GXNA29 is a score propagation method that selects random nodes as
seeds of candidate sub-networks. These are iteratively extended by adding
the neighboring node with the highest score. (f) KPM30 is another module
cover approach inspired by DEGAS. It heuristically extracts maximal
connected sub-networks, where all nodes except for at most K are
differentially expressed in a given set of samples but at most L. (g)
PinnacleZ31 is an aggregate score propagation method that extends a
set of random seed nodes to a number of sub-networks, which are
then ﬁltered by comparing their score distribution with that of
randomly generated sub-networks. We provide more details for each of
these tools in the supplementary material and brieﬂy summarize some
application cases. Please note that due to unavailability of a standalone
application, clustering-based approaches could not be considered in
our analysis.
The network data
The human protein–protein interaction (PPI) networks from the HPRD22
and the I2D23 were selected as test networks. The HPRD network consists
of 9425 nodes and 36,811 edges. I2D network consists of 17,351 nodes and
217,379 edges. The networks could be modeled as undirected graphs G
consisting of a set of vertices V and a set of edges E. To gain insights into
how network complexity affects the performance of the selected tools, we
chose two networks that differ largely in network complexity, e.g. recent
interaction networks such as I2D are orders of magnitude larger than
classical PPI networks such as HPRD.
Simulation of gene expression datasets
For each graph G, we split the nodes into FG and BG genes. Next, we
simulated expression proﬁles for a set of 110 samples, 100 patient samples
and 10 controls. Please note, we have chosen an arbitrary number of
samples in each class. This choice can also be guided by (a) random
sampling or (b) GEO GDS datasets, in order to reﬂect the median-
experiment size in real case studies. We lack it in our current study due to
limited time and computational power. We will work on this in the future,
even though we expect the main ﬁndings of our study to remain
unaffected.
We divided the simulation into three cases: (i) of patient-FG, (ii) of
control-FG, (iii) of BG for patients and controls. We used the following
models for the simulation:
(a) Varying variance. We simulated the expression proﬁles for the patient-
FG genes and—BG genes from normal distributions N(μ, vBG) ∧ N(μ, vBG)
respectively (Fig. 4a). We used the same distribution for (ii) and (iii). μ = 0
was used in all cases. Signal strength was deﬁned by the ratio vFG, vBG. See
Supplementary Table 3 for the speciﬁc values selected for variances vFG,
vBG in each scenario.
(b) Varying mean. In this case, we simulated the expression proﬁle for the
FG genes from a normal distribution N(μFG, v), while for the expression
values for BG genes we used N(μ = 0, v) and N(μFGC, v) for control-FG
(Fig. 4b). Here, we used the setting v = 1 in all cases. Signal strength was
deﬁned by the difference μFG−μFGC. See Supplementary Table 2 for the
speciﬁc values selected for means μFG, μFGC.
We further transformed the raw data into tool speciﬁc input, (e.g. p-
Fig. 4 Illustration of the used models for FG and BG expression distributions generated for cases and control samples: VV in (a) and VM in (b)
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values), the particular pre-processing steps for each tool are speciﬁed in
the supplementary material.
Selection of FG and BG nodes
We used two approaches for splitting a given graph G = (V, E) into FG and
BG nodes.
Seed and extend approach. This is a simple approach, in which we (a)
randomly selected a seed node s, (b) expanded the sub-graph by including
the nodes from the neighborhood of s, and (c) continued expanding the
neighborhood until the sub-graph s had n = 20 nodes or until the number
of nodes in the sub-graph remains the same as i−1 iteration. If the sub-
graph exceeds n, we chose n−1 neighbors randomly from the set of
neighbors.
AVDk. In this approach, the sparsity is modeled for a set of FG nodes in a
graph as the average pairwise shortest distance between them. By
generating FG node sets of varying distance k, the sparseness of the sub-
networks (or closeness of the FG genes) could be adjusted. Given a
network modeled as graph G and a sparsity level k, we deﬁne the problem
of selecting the FG nodes, as the average distance k ± α problem, or AVDK
for short. The goal was to identify a set of nodes from W⊆ V such that the
average shortest distance between all nodes of W have an average
shortest distance (in G) to each other of k ± α. If not stated otherwise, we
set α = 1. Our sparseness function ADV3, for instance, would thus return a
set of nodes (which we will later on treat as FG nodes) having, on average,
a pairwise shortest distance to each other between 2 and 4. We introduced
α parameter to allow for inexactness and variability. Finding solutions for
AVDK is computationally difﬁcult (NP-complete). We ﬁrst tackled it by using
integer-linear programming, but it proved too slow and memory intense
for graphs with thousands of nodes and edges (see Supplementary
Material). To deal with the size of current biological networks, we
developed a greedy heuristic running in polynomial time to compute
solutions for the AVDK problem. The pseudo-code and additional details
can be found in the supplementary material.
Availability. All scripts and data used in this study are available online at
http://patheval.compbio.sdu.dk.
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